Shots:

• The P-III CheckMate -9ER trial involves assessing Opdivo + Cabometyx vs sunitinib in 651 patients with previously untreated advanced or metastatic RCC
• Results: @median follow-up of two years (23.5 mos.); median PFS (17.0 vs 8.3mos.)- ORR (54.8% vs. 28.4%); Disease control rate (88.2% vs. 69.9%); CR (9.3% vs 4.3%); OS (34% reduction in risk of death). In an exploratory subgroup analysis of 75 patients with sarcomatoid features- 64% reduction in risk of death- PFS (10.3 vs 4.2mos.); ORR (55.9% vs 22.0%)
• The findings showing ongoing efficacy benefits and patient-reported outcomes will be presented at the 2021 Genitourinary Cancers Symposium

 ­ Ref: BMS | Image: BMS